Deconvolution based approach for level A in vivo/in vitro correlation modelling: Statistical considerations

Clinical Research and Regulatory Affairs

Volumn 22, Issue 1, 2005, Pages 1-14

  Dunne, Adrian ^a   Gaynor, Clare ^a   Davis, John ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Deconvolution; Level A IVIVC; Statistical Comments

Indexed keywords

ACCURACY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; REVIEW; STATISTICAL ANALYSIS; STATISTICAL MODEL; VALIDATION PROCESS;

EID: 19944416570     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1081/CRP-54957     Document Type: Review

References (38)

1. Food and Drug Administration. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. U.S. Food and Drug Administration, 1997.
2. European Agency for the Evaluation of Medicinal Products Note for Guidance on Quality of Modified Release Products: A: Oral Dosage Forms B: Transdermal Dosage Forms. European Medicines Agency, 2000.
3. Leeson LJ. In vitro/in vivo correlations. Drug Inf J 1995; 29:903-915.
4. Liu Y, Schwartz JB, Schnaare RL, Sugita ET. A multi-mechanistic drug release approach in a bead dosage form and in vitro/in vivo correlations. Pharm Dev Technol 2003; 8:409-417.
5. Sirisuth N, Augsburger LL, Eddington ND. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. Biopharm Drug Dispos 2002; 23:1-8.
6. Cardot JM, Beyssac E. In vitro/in vivo correlations: scientific implications and standardisation. Eur J Drug Metab Pharmacokinet 1993; 18:113-120.
7. Hussein Z, Friedman M. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation. Pharm Res 1990; 7:1167-1171.
8. Hayes S, Dunne A, Smart T, Davis J. Interpretation and Optimization of the Dissolution Specifications for a Modified Release Product with an In Vivo-In Vitro Correlation IVIVC. J Pharm Sci 2004; 93:571-581.
9. Devane J. The impact of in vitro-in vivo relationships on product development. Adv Exp Med Biol 1997; 423:241-260.
10. Welling PG, Forgue ST, Cook JA, DeVries TM. In vitro-in vivo correlations-quo vadis. Drug Inf J 1995; 29:893-902.
11. Polli JE, Crison JR, Amidon GL. Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci 1996; 85:753-760.
12. Gillespie WR. Convolution-based approaches for in vivo-in vitro correlation modelling. Adv Exp Med Biol 1997; 423:53-65.
13. Dunne A, O'Hara T, Devane J. Approaches to IVIVR modelling and statistical analysis. Adv Exp Med Biol 1997; 423:67-86.
14. Dowell JA, Hussain A, Devane J, Young D. Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience. J Pharm Sci 1999; 88:154-160.
15. O'Hara T, Hayes S, Davis J, Devane J, Smart T, Dunne A. In vivo-in vitro correlation IVIVC modelling incorporating a convolution step. J Pharmacokinet Pharmacodyn 2001; 28:277-298.
16. Buchwald P. Direct, differential-equation-based in-vitro-in-vivo correlation IVIVC method. J Pharm Pharmacol 2003; 55:495-504.
17. Humbert H, Cabiac MD, Bosshardt H. In vitro-in vivo correlation of a modified release oral form of ketotifen: in vitro dissolution rate specification. J Pharm Sci 1994; 83:131-136.
18. Hwang SS, Gorsline J, Louie J, Dye D, Guinta D, Hamel L. In vitro and in vivo evaluation of a once-daily controlled-release pseudoephedrine product. J Clin Pharmacol 1995; 35:259-267.
19. Mauger DT, Chinchilli VM. In vitro-in vivo relationships for oral extended-release drug products. J Biopharm Stat 1997; 7:565-578.
20. Modi NB, Lam A, Lindemulder E, Wang B, Gupta SK. Application of in vitro-in vivo correlations IVIVC in setting formulation release specifications. Biopharm Drug Dispos 2000; 21:321-326.
21. Pitsiu M, Sathyan G, Gupta S, Verotta D. A semi parametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin. J Pharm Sci 2001; 90:702-712.
22. Corrigan OI, Devlin Y, Butler J. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Int J Pharm 2003; 254:147-154.
23. Takka S, Sakr A, Goldberg A. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J Control Release 2003; 88:147-157.
24. United States Pharmacopeia. Chapter 〈711〉 Dissolution, U.S. Pharmacopeial Convention, Rockville, MD, 1995; 1791-1797.
25. Banakar UV, Makoid MC. Drug Dissolution and Bioavailability. Lancaster, PA: Technomic, 1994.
26. Gillespie WR. PCDCON: Deconvolution for pharmacokinetic applications. Documentation for PCDCON computer program. University of Texas at Austin.
27. Madden FN, Godfrey KR, Chappell MJ, Hovorka R, Bates RA. A comparison of six deconvolution techniques. J Pharmacokinet Biopharm 1996; 24:283-299.
28. Karasulu E, Aktogu S, Karasulu HY, Aydogdu A, Tugular I, Ertan G. Improving of the accuracy of in vitro-in vivo linear correlation using kinetic models for ultra sustained release theophylline tablets. Eur J Drug Metab Pharmacokinet 2003; 28:301-307.
29. Bigora S, Piscitelli D, Dowell J, Butler J, Farrell C, Devane J, Young D. Use of nonlinear mixed effects modelling in the development of in vitro-in vivo correlations. Adv Exp Med Biol 1997; 423:207-215.
30. Dunne A, Devane J, O'Hara T. The relationship between in vitro drug dissolution and in vivo absorption. Statistician 1999; 48:125-133.
31. Young D, Devane JG, Butler J. Advances in experimental medicine and biology. In Vitro-In Vivo Correlations. Vol. 423. Plenum Press: New York, 1997.
32. Polli JE. IVIVR versus IVIVC. Dissol Technol 2000; 7:6-16.
33. Rostami-Hodjegan A, Shiran MR, Tucker GT, Conway BR, Irwin WJ, Shaw LR, Grattan TJ. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. Drug Dev Ind Pharm 2002; 28:533-543.
34. Balan G, Timmins P, Greene DS, Marathe PH. In vitro-in vivo correlation IVIVC models for metformin after administration of modified-release MR oral dosage forms to healthy human volunteers. J Pharm Sci 2001; 90:1176-1185.
35. Kortejarvi H, Mikkola J, Bacjman M, Antila S, Marvola M. Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules. Int J Pharm 2002; 241:87-95.
36. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IO: Iowa State University Press, 1980.
37. Diggle PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford: Oxford University Press, 1996.
38. Wing GM. A Primer on Integral Equations of the First Kind-The Problem of Deconvolution and Unfolding. Philadelphia: Society for Industrial and Applied Mathematics, 1991.